Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

He also said 'stress can increase the drive to eat', so meditating and going for a short walk might be a good alternative to snacking. For those wanting to explore weight loss medication, he added ...

Eli Lilly, maker of Mounjaro, is a public company with a diverse product range, including weight loss drugs. Investing in Eli Lilly gives indirect exposure to Mounjaro, its top-selling product as ...

Once users stop taking Mounjaro, their appetite is no longer suppressed, and there's a decent chance that they will revert back to old eating habits and put the weight back on, but there are also ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly and Company is filing a lawsuit against Premier Weight Loss, an Indianapolis-based med spa who Lilly says is misleading patients by selling what PWL claims to be “authentic,” “FDA-approved” ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market with Novo Nordisk's Wegovy launch ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...